---
title: Safety
---

[Skip to content](https://info.interceptbloodsystem.com/safety#main-content)

[![cerus_large_2x](https://info.interceptbloodsystem.com/hubfs/Logo/cerus_large_2x.png)](https://interceptbloodsystem.com/en)

- [About](https://interceptbloodsystem.com/en/about)
- [Insights](https://insights.interceptbloodsystem.com)
- [Cerus Campus](https://info.interceptbloodsystem.com/en/cerus-campus)
- [Resources](https://interceptbloodsystem.com/en/resources)
- [Contact](https://interceptbloodsystem.com/en/contact)
- [Ask an expert](https://interceptbloodsystem.com/en/ask-expert)

## Safety

[Subscribe to our newsletter](https://interceptbloodsystem.com/en/newsletter)

## Want to stay updated on the latest pathogen inactivation news? You can receive our highlights by subscribing to our newsletter.

#### ![ThumbnailRichardWebinar1.3](https://info.interceptbloodsystem.com/hs-fs/hubfs/ThumbnailRichardWebinar1.3.png?width=650&name=ThumbnailRichardWebinar1.3.png)Platelets

## Bacterial contamination of platelet components, passive vs. active, surveillance, testing and pathogen reduction technologies

Dr. Richard J. Benjamin, MBChB, PhD, FRCPath  
Cerus Corporation,  
Concord, California, USA

### [![EN](https://no-cache.hubspot.com/cta/default/2866022/eb1160ae-705b-49d6-b0d6-e9f118f6ef07.png)](https://cta-redirect.hubspot.com/cta/redirect/2866022/eb1160ae-705b-49d6-b0d6-e9f118f6ef07)  

#### ![ThumbnailPitman](https://info.interceptbloodsystem.com/hs-fs/hubfs/ThumbnailPitman.png?width=442&name=ThumbnailPitman.png)

Platelets

## Safety surveillance and the introduction of pathogen reduced platelets: the role of national hemovigilance systems in the Cerus post-market clinical follow-up strategy

### Dr. John Pitman, PhD Cerus Corporation Concord, USA

### [![EN](https://no-cache.hubspot.com/cta/default/2866022/a060be17-65aa-4463-b11f-23693b8e6876.png)](https://cta-redirect.hubspot.com/cta/redirect/2866022/a060be17-65aa-4463-b11f-23693b8e6876)

#### ![ThumbnailAbedi-1](https://info.interceptbloodsystem.com/hs-fs/hubfs/ThumbnailAbedi-1.png?width=442&name=ThumbnailAbedi-1.png)**Platelets**

## Overview of the variability in platelet production processes and applied safety measures

### Dr. Mohammad R. Abedi, PhD Örebro University Hospital Örebro, Sweden

### [![EN](https://no-cache.hubspot.com/cta/default/2866022/b0f42383-89bc-4046-8776-2ee7e638a720.png)](https://cta-redirect.hubspot.com/cta/redirect/2866022/b0f42383-89bc-4046-8776-2ee7e638a720)

[Back](https://info.interceptbloodsystem.com/cerus_campus?hsLang=de)

![cerus_large_2x](https://info.interceptbloodsystem.com/hubfs/Logo/cerus_large_2x.png)

- [Legal Info](https://interceptbloodsystem.com/en/legal-info)
- [Privacy Policy](https://interceptbloodsystem.com/en/privacy-policy)
- [Cookies](https://interceptbloodsystem.com/en/cookie-policy-and-tracking-opt-out-guide)

The information on this site is not country-specific, and may contain information that is outside the approved indications for the country in which you are located.  
Use of INTERCEPT Plasma or Platelets is contraindicated in patients with a history or allergic response to amotosalen or psoralens. Consult instructions for use for indications, contraindications, warnings, and precautions.

Cerus, INTERCEPT and the Cerus logo are trademarks of Cerus Corporation.

© 2023 Cerus Corporation. All Rights Reserved. MKT-EN 000157, v43.0